Orforglipron vs AOD-9604
Compare the research profiles of Orforglipron and AOD-9604. Read the individual guides for evidence and limitations.
How to interpret this comparison
This page summarizes database profiles and has not yet received a study-by-study editorial review. Use the linked guides and primary sources to evaluate a specific claim.
How to read peptide studiesOrforglipron
Orforglipron (LY3502970)
weight-loss
Phase 3 Clinical Trials
clinical-trials
AOD-9604
AOD-9604 (Anti-Obesity Drug)
weight-loss
Phase 2 Clinical Trials (discontinued)
not-approved
Detailed Comparison
| Aspect | Orforglipron | AOD-9604 |
|---|---|---|
| Overview | The most anticipated upcoming weight loss drug - the first oral non-peptide GLP-1 receptor agonist. Unlike current oral options, it does not require fasting before consumption, potentially removing a ... | A fragment of human growth hormone (amino acids 177-191) marketed specifically for fat burning without affecting blood sugar or causing GH-related side effects. Now banned from compounding by FDA.... |
| Research topics (not established benefits) |
|
|
| Side Effects |
|
|
| Mechanism | Small molecule that activates GLP-1 receptors orally without the peptide structure. Provides similar effects to injectable GLP-1s but in pill form.... | Mimics the fat-burning effects of growth hormone without affecting blood sugar or cell proliferation. Stimulates lipolysis (fat breakdown) and inhibit... |
Frequently Asked Questions
Does a comparison establish which treatment is better?
Only appropriately designed evidence for the same clinical question can support that conclusion. Database categories and mechanisms alone cannot rank treatments.
Does this page establish that these compounds can be combined?
No. This page does not assess interactions or the benefit and safety of combined use. Individual studies cannot establish the effects of a combination.